Q-omics provides the consensus-scored PMPCB profile across patient tissues and cancer cell-line models. PMPCB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PMPCB is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PMPCB protein abundance shows 25,774 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, COAD, and GBM as cancer lineages where PMPCB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMPCB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMPCB survival associations across molecular data types. PMPCB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMPCB RNA expression–survival associations across cancer types. High PMPCB expression shows unfavorable associations in LGG, KICH, SCLC and UVM, but favorable associations in BRCA and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for PMPCB RNA expression.
This table summarizes PMPCB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PMPCB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMPCB shows higher tumor expression in COAD, LUAD, LIHC, KICH, CHOL and ESCA. The COAD box plot shows higher PMPCB RNA expression in tumor versus normal tissue (log2 FC = +0.518, t-test p < 0.001).
This table shows molecular features associated with PMPCB in patient tissues and cancer cell lines. In patient samples, PMPCB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PMPCB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
